Ronald Levy
17Patents
7h-index
38Co-inventors
66Inventor score
Filing activity: Mar 30, 1983 → Jan 31, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7332280B2 | Classification of patients having diffuse large B-cell lymphoma based upon gene expression | Chemistry; Metallurgy | 77 | Expired |
| US9005619B2 | Methods for enhancing anti-tumor antibody therapy | Physics | 33 | Active |
| US4661586A | Monoclonal anti-idiotype antibodies | Emerging Cross-Sectional Technologies | 32 | Expired |
| US9758589B2 | Methods for enhancing anti-tumor antibody therapy | Physics | 24 | Active |
| US5512435A | Receptor-binding antiproliferative peptides | Emerging Cross-Sectional Technologies | 23 | Expired |
| US4816249A | Monoclonal anti-idiotype antibodies | Emerging Cross-Sectional Technologies | 18 | Expired |
| US4513088A | Assay for monoclonal antibody against surface Ig of a human B cell tumor | Emerging Cross-Sectional Technologies | 15 | Expired |
| US6099846A | Enhancement of B cell lymphoma and tumor resistance using idiotype/cytokine conjugates | Chemistry; Metallurgy | 6 | Expired |
| US8481045B2 | Immunogenic protein constructs | Chemistry; Metallurgy | 4 | Active |
| US10633450B2 | Methods for enhancing anti-tumor antibody therapy | Physics | 3 | Active |
| US10040862B2 | Humanized and chimeric monoclonal antibodies to CD99 | Chemistry; Metallurgy | 1 | Active |
| US7622253B2 | Classification of patients having diffuse large b-cell lymphoma based upon gene expression | Chemistry; Metallurgy | 1 | Active |
| US9605320B2 | Method of predicting responsiveness of B cell lineage malignancies to active immunotherapy | Physics | 0 | Active |
| US9109255B2 | Methods and compositions for determining responsiveness to antibody therapy | Chemistry; Metallurgy | 0 | Active |
| US10815306B2 | Humanized and chimeric monoclonal antibodies to CD81 | Chemistry; Metallurgy | 0 | Active |
| US11931416B2 | Immolative cell-penetrating complexes for nucleic acid delivery to the lung | Chemistry; Metallurgy | 0 | Active |
| US12215341B2 | Hybrid immolative cell-penetrating complexes for nucleic acid delivery | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.